Generic Name and Formulations:
Trifluridine 1%; oph. soln; contains thimerosal.
Indications for VIROPTIC:
Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex types 1 and 2.
Adults and Children:
<6yrs: not recommended. Do not exceed recommended dose. ≥6yrs: 1 drop every 2hrs while awake; max 9 drops/day. After reepithelialization, 1 drop every 4hrs for 7 days (at least 5 drops/day); max 21 days therapy. Reevaluate if no improvement in 7 days or incomplete reepithelialization in 14 days.
Glaucoma. Pregnancy (Cat.C). Nursing mothers.
Transient ocular burning or stinging, keratopathy, edema, irritation, keratitis sicca, hyperemia, increased intraocular pressure.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|